FR-Targeting Agents for Dendritic Cell Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to isolate and target first responder dendritic cells (FRs), which are crucial for initiating bulk innate cell TLR-mediated activation, limiting the development of targeted vaccine compositions and immunotherapeutics.
Innovation Solution
Development of pharmaceutical compositions comprising an antigen and an FR-targeting agent, along with methods for isolating and stimulating immune responses by targeting FRs using specific agents such as PRG2-binding agents, DAP12-binding agents, and TLR agonists like CpG oligodeoxynucleotides, to enhance antigen presentation and immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antigen presentation methods are used, then antigen presentation occurs, but the precision and efficacy of targeting first responder dendritic cells is insufficient
Solution Approach 1:
The patent employs TLR agonists as intermediary molecules that specifically bind to TLR receptors on first responder dendritic cells. This intermediary approach enables precise targeting of FRs through the TLR signaling pathway, resolving the contradiction between targeting precision and immune activation efficacy by using a mediator that naturally recognizes and activates this specific cell population.
Solution Approach 2:
The patent utilizes changes in TLR receptor expression and activation parameters to identify and target first responder dendritic cells. By monitoring and exploiting parameter changes such as TLR4 upregulation and cytokine secretion patterns, the invention achieves precise targeting while maintaining reliable immune activation through parameter-based cell state recognition.
2Reliability
If bulk immune cell activation is stimulated, then immune response is activated, but the ability to specifically isolate and target first responder dendritic cells is limited
Solution Approach 1:
The patent extracts and isolates first responder dendritic cells from bulk immune cell populations by exploiting their unique TLR agonist uptake characteristics. Using flow cytometry to detect TLR agonist-conjugated microparticle uptake, the invention separates FRs from other immune cells, achieving precise cell isolation while maintaining their activation capability.
Solution Approach 2:
The patent replaces mechanical separation methods with a biochemical detection system based on TLR agonist binding. By using fluorescently labeled TLR agonist-conjugated microparticles and flow cytometry, the invention substitutes physical isolation techniques with a molecular recognition approach that specifically identifies FRs through their TLR receptor expression and agonist uptake behavior.
3Productivity
If non-specific antigen delivery is used, then antigen distribution is broad, but the efficacy of stimulating first responder dendritic cells is reduced
Solution Approach 1:
The patent applies preliminary action by pre-conjugating TLR agonists to microparticles or nanoparticles before antigen delivery. This preliminary functionalization ensures that the delivery vehicle is pre-equipped with targeting capability, allowing it to specifically recognize and bind to first responder dendritic cells upon administration, thereby improving both efficiency and ease of targeted delivery.
Solution Approach 2:
The patent employs composite material structures consisting of TLR agonist-conjugated microparticles or nanoparticles combined with antigens. These composite delivery systems integrate targeting moieties (TLR agonists) with cargo (antigens) in a single functional unit, enabling simultaneous targeted delivery and immune stimulation while simplifying the overall delivery process.
Data Source
AI summary
Disclosed herein are methods and compositions related to identification, isolation, and targeting of first responder dendritic cells (FRs). Aspects of the disclosure are directed to FR-targeting agents and methods for use of such agents, including methods for directing a diagnostic, imaging, or therapeutic molecule (e.g., an antigen) to FRs. The present disclosure includes pharmaceutical compositions comprising an FR-targeting agent and an antigen or polynucleotide encoding an antigen. Also disclosed are methods for stimulating an immune response comprising targeting an antigen to FRs.